Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts sayMarket Watch • 08/26/24
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASISPRNewsWire • 08/20/24
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a DecadeThe Motley Fool • 08/18/24
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the PipelineThe Motley Fool • 08/17/24
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical ReadoutsBenzinga • 08/07/24
Amgen Is Redoubling Its Efforts To Take On Weight-Loss Kingpins Novo, LillyInvestors Business Daily • 08/06/24
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 08/06/24
Dow Jones Biotech Amgen, MercadoLibre, Ferrari Hold Up In Shaken MarketInvestors Business Daily • 08/05/24